AETHLON MEDICAL INCAEMDEarnings & Financial Report
Aethlon Medical Inc. is a clinical-stage medical technology firm that develops targeted therapeutic devices to address life-threatening health conditions. Its lead product, the Hemopurifier, is designed to remove harmful viruses, cancer-derived exosomes, and other pathogens from the bloodstream. The company primarily operates in the infectious disease and oncology healthcare segments, with main market presence in North America.
AEMD Q3 FY2025 Key Financial Metrics
Revenue
$60.0K
Gross Profit
N/A
Operating Profit
$-1.8M
Net Profit
$-1.8M
Gross Margin
N/A
Operating Margin
-3026.4%
Net Margin
-2926.4%
YoY Growth
N/A
EPS
$-10.05
AETHLON MEDICAL INC Q3 FY2025 Financial Summary
AETHLON MEDICAL INC reported revenue of $60.0K for Q3 FY2025, with a net profit of $-1.8M (up 49.4% YoY) (-2926.4% margin).
Key Financial Metrics
| Total Revenue | $60.0K |
|---|---|
| Net Profit | $-1.8M |
| Gross Margin | N/A |
| Operating Margin | -3026.4% |
| Report Period | Q3 FY2025 |
AETHLON MEDICAL INC Quarterly Revenue & Net Profit History
AETHLON MEDICAL INC results over the last 2 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $60.0K | — | $-1.8M | -2926.4% |
| Q2 FY2025 | $95.1K | — | $-2.8M | -2950.2% |
Income Statement
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Revenue | $95146 | $59964 |
| YoY Growth | N/A | N/A |
Balance Sheet
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Assets | $8.8M | $6.5M |
| Liabilities | $2.8M | $2.2M |
| Equity | $6.0M | $4.3M |
Cash Flow
| Q2 2025 | Q3 2025 | |
|---|---|---|
| Operating CF | $-2.2M | $-2.0M |